COMMENTARY

Should Everyone Take Metformin?

Gregory A. Nichols, PhD

Disclosures

December 04, 2014

In This Article

Initial Choice of Oral Glucose-Lowering Medication for Diabetes Mellitus: A Patient-Centered Comparative Effectiveness Study

Berkowitz SA, Krumme AA, Avorn J, et al
JAMA Intern Med. 2014 Oct 27. [Epub ahead of print]

With All the New Classes of Drugs, Is Metformin Still the First Choice?

This observational cohort study sought to determine the effect of initial oral glucose-lowering class on subsequent need for additional anti-hyperglycemia therapy. Participants included 15,516 patients who were not previously treated for diabetes, in whom therapy with metformin, a sulfonylurea (SU), a thiazolidinedione (TZD), or a dipeptidyl peptidase 4-inihibitor (DPP4) was initiated. The primary outcome was time to treatment intensification, defined as initiation of a different class of oral glucose-lowering medication.

Secondary outcomes included time to composite cardiovascular event (coronary heart disease, congestive heart failure, unstable angina, ischemic stroke, acute myocardial infarction, or a revascularization procedure), congestive heart failure alone, an emergency department visit or hospital admission for hypoglycemia, and any other diabetes-related emergency department visit. The analyses used Cox proportional hazards models with a large number of covariates to adjust for differences in demographic characteristics, comorbidities, and medical utilization.

The Winner, and Still Champion: Metformin

Among the initial group of patients, 58% began therapy with metformin, 23% with an SU, 6% with a TZD, and 13% with a DPP4. During similar median follow-up of slightly more than 1 year, subsequent treatment intensification differed significantly by drug class. Of patients prescribed metformin, 25% required a second oral agent, compared with 37% of SU recipients, 40% of TZD recipients, and 36% of patients taking a DPP4. These results held in multivariable analysis.

Relative to metformin users, the risk for treatment intensification was 68% greater among SU users, 61% greater among TZD users, and 62% greater among DPP4 users. Also relative to metformin, SU use was associated with an increased risk for composite cardiovascular events, congestive heart failure, and hypoglycemia.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....